Literature DB >> 28115553

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.

Kenichi Fukumoto1, Hidetoh Toki1, Michihiko Iijima1, Takashi Hashihayata1, Jun-Ichi Yamaguchi1, Kenji Hashimoto1, Shigeyuki Chaki2.   

Abstract

The rapid-acting and long-lasting antidepressant effects of (R,S)-ketamine have recently gained much attention. Although (S)-ketamine has been studied as an active isomer, recent evidence suggests that (R)-ketamine exhibits longer-lasting antidepressant effects than (S)-ketamine in rodents. However, the antidepressant potential of (R)-ketamine has not been fully addressed. In the present study, we compared the antidepressant effects of (R)-ketamine with those of (S)-ketamine in animal models of depression, including a model that is refractory to current medications. Both (R)-ketamine and (S)-ketamine exhibited antidepressant effects at 30 minutes as well as at 24 hours after administration in forced-swimming and tail-suspension tests in mice. At 48 hours after administration, however, (R)-ketamine still exerted a significant antidepressant effect in the tail-suspension test, whereas the effect of (S)-ketamine was no longer observed. Moreover, (R)-ketamine, but not (S)-ketamine, significantly reversed the depressive-like behavior induced by repeated treatments with corticosterone in rats at 24 hours after a single administration. This effect was attenuated by an α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist, suggesting the involvement of AMPA receptor stimulation in the effects. Both (R)-ketamine and (S)-ketamine exhibited practically the same exposure levels in plasma, brain, and cerebrospinal fluid in mice and rats, and both compounds were rapidly eliminated from plasma (<4-8 hours). The present results confirmed the previous findings that (R)-ketamine exerted longer-lasting antidepressant effects than (S)-ketamine in animal models of depression. Moreover, our study is the first to demonstrate that (R)-ketamine exerted a sustained antidepressant effect even in a model that is refractory to currently prescribed antidepressants.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28115553     DOI: 10.1124/jpet.116.239228

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  66 in total

1.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

2.  Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model.

Authors:  Lijia Chang; Kai Zhang; Yaoyu Pu; Youge Qu; Si-Ming Wang; Zhongwei Xiong; Yukihiko Shirayama; Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-03-29       Impact factor: 5.270

3.  Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.

Authors:  Brendan D Hare; Santosh Pothula; Ralph J DiLeone; Ronald S Duman
Journal:  Neuropharmacology       Date:  2020-01-09       Impact factor: 5.250

4.  Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions.

Authors:  Panos Zanos; Todd D Gould
Journal:  Biol Psychiatry       Date:  2018-01-01       Impact factor: 13.382

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 6.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 7.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

8.  Alternatives to ketamine in depression: state-of-the-art and future perspectives.

Authors:  Luke A Jelen; Sinead King; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2017-12-18

Review 9.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

10.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.